ArticleFrontiers in oncology2022

The benefit of bevacizumab therapy in patients with refractory vasogenic edema caused by brain metastasis from lung and colon cancers.

Xuexue Bai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.